PartagerCasques réfrigérants : prévenir la perte des cheveux liée à la chimiothérapie.
Le casque réfrigérant pourrait réduire la perte des cheveux dûe au traitement du cancer du sein par chimiothérapie.
Chemotherapy may result in hair loss (alopecia), which woman rate as one of the most distressing adverse effect of chemotherapy.
Two recent studies published in the February 14 issue of the Journal of the American Medical Association (JAMA) examine alopecia among women with breast cancer who received scalp cooling before, during and after chemotherapy.
These studies were conducted between 2013 and 2016 and concerned respectively 182 and 126 women.
In the first study conducted by Julie Nangia, Tao Wang, Cynthia Osborne, et al, scalp cooling began 30 minutes before each chemotherapy infusion and lasted 90 minutes after it. Hair preservation was assessed at the end of four cycles of chemotherapy. The researchers found that woman who underwent scalp cooling were significantly more likely to have less than 50% hair loss compared with no scalp cooling. It means that this scalp cooling system was more likely to prevent alopecia than no treatment, and further research is needed to assess longer-term efficacy and adverse effects.
In the second study conducted by Hope S. Rugo, Paula Klein, Susan Anitra Melin, et al, the researchers tried to evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. The average duration of chemotherapy was 2.3 months. Hair loss of 50 percent or less was seen in 67 of 101 patients (66 percent) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0 percent) in the control group. Three of five quality-of-life measures were significantly better one month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27 percent reported feeling less physically attractive compared with 56 percent of patients in the control group. Of the 106 patients in the scalp cooling group, four (3.8 percent) experienced the adverse event of mild headache and three (2.8 percent) discontinued scalp cooling due to feeling cold.
Although scalp cooling has been available for several decades in Europe, its use has been limited in the United States because of several factors, including insufficient prospective efficacy data with current chemotherapy regimens and lack of U.S. Food and Drug Administration (FDA) clearance.
For further information, please consult Science Daily website.
This information is available in French on the Figaro Santé website.
Two recent studies published in the February 14 issue of the Journal of the American Medical Association (JAMA) examine alopecia among women with breast cancer who received scalp cooling before, during and after chemotherapy.
These studies were conducted between 2013 and 2016 and concerned respectively 182 and 126 women.
In the first study conducted by Julie Nangia, Tao Wang, Cynthia Osborne, et al, scalp cooling began 30 minutes before each chemotherapy infusion and lasted 90 minutes after it. Hair preservation was assessed at the end of four cycles of chemotherapy. The researchers found that woman who underwent scalp cooling were significantly more likely to have less than 50% hair loss compared with no scalp cooling. It means that this scalp cooling system was more likely to prevent alopecia than no treatment, and further research is needed to assess longer-term efficacy and adverse effects.
In the second study conducted by Hope S. Rugo, Paula Klein, Susan Anitra Melin, et al, the researchers tried to evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. The average duration of chemotherapy was 2.3 months. Hair loss of 50 percent or less was seen in 67 of 101 patients (66 percent) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0 percent) in the control group. Three of five quality-of-life measures were significantly better one month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27 percent reported feeling less physically attractive compared with 56 percent of patients in the control group. Of the 106 patients in the scalp cooling group, four (3.8 percent) experienced the adverse event of mild headache and three (2.8 percent) discontinued scalp cooling due to feeling cold.
Although scalp cooling has been available for several decades in Europe, its use has been limited in the United States because of several factors, including insufficient prospective efficacy data with current chemotherapy regimens and lack of U.S. Food and Drug Administration (FDA) clearance.
For further information, please consult Science Daily website.
This information is available in French on the Figaro Santé website.